EKF Diagnostics Holdings plc (AIM:EKF)

London flag London · Delayed Price · Currency is GBP · Price in GBX
31.90
+0.80 (2.57%)
Sep 9, 2025, 8:01 AM GMT+1
2.57%
Market Cap138.32M
Revenue (ttm)50.19M
Net Income (ttm)6.24M
Shares Out449.09M
EPS (ttm)0.01
PE Ratio22.39
Forward PE21.39
Dividendn/a
Ex-Dividend Daten/a
Volume200
Average Volume385,690
Open31.00
Previous Close31.10
Day's Range31.00 - 31.90
52-Week Range18.40 - 32.00
Beta0.20
RSI59.19
Earnings DateSep 16, 2025

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl... [Read more]

Sector Healthcare
Founded 1990
Employees 303
Stock Exchange London Stock Exchange AIM
Ticker Symbol EKF
Full Company Profile

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.

Financial Statements

News

There is no news available yet.